Nanox (NNOX) Q4 2025 earnings review
Core Hardware Revenue Collapses Amid Strategic Pivot and Write-Downs
Nanox missed on core system commercialization as Imaging Systems revenue collapsed to just $49,000 in Q4, severely contradicting management's narrative of 'strong momentum' and 'advanced commercialization.' Total revenue grew 24% YoY to $3.7M strictly on the back of its legacy teleradiology business and the newly acquired Vaso Healthcare IT. Net loss ballooned 137% YoY to $33.4M, driven by a massive $17.5M impairment charge as the company abruptly closes its South Korean chip manufacturing facility to outsource production. While the aggressive $35M revenue target for FY26 is maintained, the severe gap between the touted hardware deployment pipeline and actual revenue generation raises massive execution flags.
🐂 Bull Case
The acquisition of Vaso Healthcare IT immediately contributed $400k in Q4 revenue, instantly scaling the previously anemic AI/Software division and providing a new US customer base.
A new agreement with Howard Technology Solutions targets the deployment of 300 Nanox.ARC systems over three years, theoretically expanding the commercial footprint if execution follows.
🐻 Bear Case
Despite claiming 36 systems deployed and 360 systems under agreement, actual Imaging Systems revenue was a minuscule $49,000 in Q4—costing the company $2.6M in gross losses to generate.
The $17.5M impairment charge to close the South Korean chip manufacturing line represents a costly strategic reversal, shifting reliance to third-party manufacturers like CSEM.
⚖️ Verdict: 🔴
Bearish. The reliance on legacy teleradiology and a timely acquisition to mask the sequential collapse of Nanox.ARC revenue—combined with a sudden $17.5M write-down of their proprietary manufacturing fab—signals deep structural challenges.
Key Themes
The Imaging Revenue Disconnect
Reversing. Management's press release touts 'advanced commercialization' and 'distribution agreements for approximately 360 Capex systems.' This narrative directly contradicts the financials: Imaging Systems revenue fell sequentially from $221k in 25Q2, to $175k in 25Q3, to a staggering $49k in 25Q4. Furthermore, generating this $49k cost the company $2.6M in GAAP gross losses. The inability to translate deployed systems into meaningful, profitable revenue is the primary red flag for investors.
Abrupt Manufacturing Restructuring
The company is completely abandoning its vertically integrated manufacturing strategy. By closing the chip manufacturing line at its South Korean fab and transferring production to third parties (CSEM), Nanox took a $17.5M impairment charge. While management claims this will 'align the manufacturing cost structure,' it represents a massive sunk cost and introduces new third-party supply chain risks for the Nanox.ARC platform.
Vaso Healthcare IT Masks AI Weakness
Accelerating. The AI and Software segment saw revenue jump to $0.5M in Q4 from $142k in Q3. However, $0.4M of this Q4 revenue was generated entirely by the newly acquired Nanox Health IT (Vaso) over just six weeks. This acquisition effectively rescued the segment's optical growth, masking the stagnation of the core Nanox.AI product.
Teleradiology as the Sole Stabilizer
Stable. The teleradiology segment remains the only functioning core business, generating $3.1M in Q4 revenue (up from $2.8M YoY) with a GAAP gross margin of 27% (48% non-GAAP). This segment provides the only organic cash generation keeping the broader ecosystem afloat.
Intense Cash Burn and Dilution
Operating cash outflow reached $40.8M for FY25. To fund this burn, Nanox is leaning heavily on retail and institutional dilution, selling 4.2 million shares through its ATM facility in Q4 alone to raise $15.5M. Total cash and marketable securities dwindled to $60.0M, down from $83.5M at the end of 2024.
Clinical and Commercial Tech Validation
Nanox continues to push the clinical utility of its software, adding Cedars Sinai as a clinical trial partner to evaluate the Nanox.AI aortic valve calcification solution. Establishing peer-reviewed credibility is a prerequisite for broader hospital adoption.
Geopolitical Macro Risks Persist
The company explicitly noted the ongoing geopolitical situation in the Middle East. While operations are currently undisrupted, Nanox is an Israel-headquartered company. Regional escalations pose a constant, unquantifiable tail-risk to executive operations and local partnerships.
Other KPIs
Stable but abysmal. The company generated $3.7M in revenue but recorded a $3.6M gross loss. The cost to deploy and service the Nanox.ARC systems vastly outweighs the revenue they currently generate, neutralizing the positive margins from the teleradiology business.
Decelerating. Down from $5.4M in 24Q4. This supports management's claim that they are shifting from an R&D-focused organization to a commercialization phase, though the commercial results have yet to materialize.
Guidance
Accelerating dramatically. Achieving this would require a ~169% YoY growth from FY25's $13.0M. Given the company generated only $3.7M in Q4, the required run-rate implies a steep, back-end loaded ramp that relies heavily on theoretical CapEx sales from distribution partners rather than proven historical traction.
Key Questions
Imaging Revenue Disconnect
With 36 Nanox.ARC systems deployed and agreements for 360 more, why did recognized Imaging Systems revenue collapse sequentially to just $49,000 in Q4? What are the specific bottlenecks preventing revenue recognition on active machines?
Bridge to $35M Guidance
Can you break down the $35M FY26 revenue guidance? Specifically, how much is projected to come from legacy teleradiology, the new Vaso Health IT baseline, versus actual Nanox.ARC system sales?
Supply Chain Continuity
Following the closure of the South Korean chip manufacturing line, how much emitter inventory do you currently hold, and what is the exact timeline for CSEM to reach full-scale, commercial-grade production?
CFO Transition Timing
With Ran Daniel departing in July and Guy Nathanzon joining, will there be any shifts in capital allocation strategy or changes to the current ATM utilization program during this transition period?